Press Releases Latest Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Press Releases Year None202420232022202120202019201820172016201520142013 Sep 22, 2021 Theratechnologies Announces Positive Results for Trogarzo® IV Push Administration Study Sep 16, 2021 Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021 Sep 07, 2021 Theratechnologies to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Sep 01, 2021 Theratechnologies to Host Key Opinion Leader Event to Discuss Tesamorelin for the Treatment of Non-Alcoholic Steatohepatitis (NASH) Aug 13, 2021 Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science Aug 04, 2021 Theratechnologies to Present at the Canaccord Genuity 41st Annual Growth Conference Jul 23, 2021 Theratechnologies Establishes New At-The-Market Facility Jul 15, 2021 Theratechnologies Reports Financial Results for the Second Quarter of Fiscal 2021 and Provides Update on Its Planned Phase 3 Clinical Trial in NASH Jun 30, 2021 Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021 Jun 23, 2021 Theratechnologies Appoints New Board Member First page « Previous page ‹ … Page 9 Page 10 Page 11 Page 12 Current page 13 Page 14 Page 15 Page 16 Page 17 … Next page › Last page » Displaying 121 - 130 of 379
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Sep 16, 2021 Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021
Sep 07, 2021 Theratechnologies to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 01, 2021 Theratechnologies to Host Key Opinion Leader Event to Discuss Tesamorelin for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Aug 13, 2021 Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science
Jul 15, 2021 Theratechnologies Reports Financial Results for the Second Quarter of Fiscal 2021 and Provides Update on Its Planned Phase 3 Clinical Trial in NASH
